Table 2. Compliance and drug delivery.
| CE (n=110) | SPE (n=109a) | P-value | |
|---|---|---|---|
| Median interval of each chemotherapy (days) (range) | |||
| 1–2 | 27 (14–35) | 23 (20–37) | 0.02b |
| 2–3 | 25 (21–56) | 22 (20–35) | 0.07b |
| 3–4 | 27 (21–36) | 24 (21–38) | 0.05b |
| Total delivered courses/projected courses | 353/440 (80%) | 360/436 (83%) | |
| Dose reduction | 32 (29%) | 11 (10%) | <0.01c |
| Course delay | 45 (41%) | 40 (37%) | 0.58c |
| G-CSF delivery | 81 (74%) | 84 (77%) | 0.64c |
| No. of courses with G-CSF delivery/number of total courses | 183/354 (52%) | 203/362 (56%) | |
CE, carboplatin plus etoposide; G-CSF, granulocyte colony-stimulating factor; SPE, split doses of cisplatin plus etoposide.
a
One patient never received chemotherapy due to delirium after registration.
b
Wilcoxon rank-sum test.
c
Fisher’s exact test.